Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403699 · ClinicalTrials.gov registry record
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
A clinical trial of Diabetic Retinopathy and Diabetes Complications, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03403699 is a study of Diabetic Retinopathy and Diabetes Complications that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03403699, a study of Diabetic Retinopathy and Diabetes Complications, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects with diabetes and age matched controls. The human iPSC cells will be used to generate mesoderm cells for injection into the vitreous cavity of diabetic rodents and primate eyes. The ability of mesoderm cells to generate endothelial cells and pericytes in areas of degenerated capillaries will be examined. The human iPSCs will also be used to generate hematopoietic CD34+CD45+ cells. The combination of CD34+CD45+ cells derived from iPSCs and iPSC derived mesoderm will be examined in combination for their potentially beneficial effect to enhance the vessel formation.
Conditions Studied
Interventions
- BIOLOGICAL Generation of inducible pluripotent stem cells
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403699
The ClinicalTrials.gov registry entry for NCT03403699 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Generation of inducible pluripotent stem cells is the first listed.
NCT03403699 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03403699 about?
NCT03403699 is a clinical study titled "Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy". This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects w...
What is the current status of trial NCT03403699?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2018-01-11. Estimated completion is 2027-12-31.
What conditions does trial NCT03403699 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Diabetes Complications.
What interventions are being tested in trial NCT03403699?
The interventions under investigation include: Generation of inducible pluripotent stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03403699?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03403699 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.